Abstract
Aim: to analyze the influence of the immunomodeling preparation glutamyl-cysteinyl-glycine disodium (glutoxim) on indices of cellular and humoral immunity in patients with pneumonias on the background of acute myeloblast leucosis to form new approaches to the improvement of treating pneumonias in patients with immunity disorders. Materials and methods. The research group - 37 patients with pneumonia on the background of acute myeloblast leucosis, who underwent the program treatment on the base of the hematological center “MI city multi-profile clinical hospital №4” Dnipro city, 2014-2015. The age of patients from 23 to 45 years old; 10 women and 27 men. The diagnosis of leucosis and pneumonia forms was verified corresponding to modern conventional clinical and morphological criteria. Patients from the main research group (n = 18) were prescribed with glutamyl-cysteinyl-glycine disodium by the scheme 2 ml of 3 % (60 mg) i/v № 10 in mornings, summary dose - 300 mg. Indications of immunograms were studied: Т-lymphocytes, В-lymphocytes and their subpopulation composition (CD3 +, CD4 +, CD8 +, CD19 +, CD19-, CD16 +, CD56+) using the flowing laser cytofluorimetry. Immunoglobulin levels were determined by the method of immunoturbometry. Indications of immunograms were assessed in the treatment dynamics. The statistical processing – using packages of applied programs «Excel» and «Statistic 10». Results. According to the analysis of indices of the cellular and humoral immunity of patients with pneumonia on the background of acute myeloblast leucosis, the process of glutamyl-cysteinyl-glycine disodium use proved the statistically reliable activation of phagocytosis and anti-infectious defense indices. The dynamics of humoral immunity indices also proved the positive influence on the state of the immune reactivity of the organism with the reliable increase of ІgА and Іg М, responsible for neutralization of infectious agents and bacterial toxins. Conclusions: The use of the ummunomodeling preparation glutamyl-cysteinyl-glycine disodium (glutoxim) in patients with pneumonia on the background of acute myeloblast leucosis results in the improvement of indices of cellular and humoral immunity and phagocytosis activation. The research results prove the possibility of optimization of approaches to treating pneumonias in patients with severe immunity disorders by using immunomedeling therapy by glutamyl-cysteinyl-glycine disodium (glutoxim). KEYWORDS
Highlights
The pathogenetic background of acute leucosis (AL) is a cellular immunity defect, manifested by the change of quantitative indices and functional disability of Т-lymphocytes and monocytic-phagocytic system
The incorrect antibacterial therapy intensifies the expressiveness of the immunodeficiency syndrome and leads to the formation of resistant nosocomial flora that is very difficultly subjected to elimination in patients with pneumonia on the background of AL [3]
Materials and methods The research group consisted of 37 patients with pneumonia, developed at the background of acute non-lymphoblast leucosis (AnonLL), who underwent the program treatment according to the form and stage of the disease on the base of the hematological center “MI of city multi-profile clinical hospital No 4”, Dnipro city
Summary
The pathogenetic background of acute leucosis (AL) is a cellular immunity defect, manifested by the change of quantitative indices and functional disability of Т-lymphocytes and monocytic-phagocytic system. Corticosteroids, combined with cytostatics negatively influence the patient’s immunity state On this background severe infectious-inflammatory complications, including pneumonias that often result in patients’ death are observed in patients with AL in more than 50 % cases [2]. The incorrect antibacterial therapy intensifies the expressiveness of the immunodeficiency syndrome and leads to the formation of resistant nosocomial flora that is very difficultly subjected to elimination in patients with pneumonia on the background of AL [3]. In this connection the strategy of using only etiotropic antibacterial therapy (ABT) at pneumonias in patients with AL doesn’t lead to expected results
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
